Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $75.12M by Medicaid between Jan 2018 and Dec 2024, across 376 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
PANORAMA CITY, CA 91402
PANORAMA CITY, CA 91402
33aNPI1376698043assigned 01/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$75.12M
24GClaims1,685,644
24DCodes billed376
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#36 of 410
Median peer was paid$6.90M
This provider vs. median11×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 153,030 | $669K | |
| 2019 | 231,405 | $9.05M | |
| 2020 | 229,624 | $15.73M | |
| 2021 | 215,545 | $10.01M | |
| 2022 | 244,753 | $12.00M | |
| 2023 | 292,713 | $12.76M | |
| 2024incomplete | 318,574 | $14.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 54,740 | 50,374 | $23.99M |
| G0378 | Hospital observation service, per hour | 15% | 8,161 | 5,494 | $11.61M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.4% | 7,479 | 7,222 | $5.52M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 4.7% | 2,931 | 2,856 | $3.55M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 7,638 | 7,492 | $2.43M |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 2.5% | 1,530 | 1,529 | $1.85M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 6,132 | 5,982 | $1.47M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.8% | 898 | 896 | $1.34M |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 1.4% | 9,926 | 9,919 | $1.08M |
| 0450 | Emergency room services | 1.3% | 22,489 | 20,460 | $972K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.1% | 8,220 | 7,970 | $852K |
| 71045 | Radiologic examination, chest; single view | 1.1% | 14,408 | 13,570 | $831K |
364 more codes
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,929 | $715K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,654 | $695K |
| 78499 | <1% | 1,108 | $607K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 16,526 | $554K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,641 | $539K |
| 86900 | <1% | 8,573 | $486K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,504 | $480K |
| 76830 | Ultrasound, transvaginal | <1% | 5,211 | $464K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,077 | $454K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,230 | $425K |
| 93017 | <1% | 936 | $412K | |
| 86885 | <1% | 5,895 | $405K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 80,490 | $370K |
| 80051 | <1% | 84,359 | $326K | |
| 82565 | <1% | 92,784 | $309K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 9,020 | $285K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,144 | $274K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,457 | $268K |
| 76770 | <1% | 2,578 | $251K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,240 | $230K |
| 73630 | <1% | 3,820 | $222K | |
| 84460 | <1% | 57,154 | $219K | |
| 76641 | <1% | 2,537 | $218K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,682 | $210K |
| 73562 | <1% | 3,257 | $197K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 23,158 | $196K |
| 83880 | <1% | 11,047 | $192K | |
| 80061 | Lipid panel | <1% | 14,959 | $188K |
| 87505 | <1% | 1,812 | $184K | |
| 73030 | <1% | 2,833 | $180K | |
| 85027 | <1% | 38,207 | $179K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 799 | $178K |
| 71250 | <1% | 1,342 | $177K | |
| 76536 | <1% | 1,751 | $175K | |
| 73610 | <1% | 3,241 | $172K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,794 | $171K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,596 | $170K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,598 | $170K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,851 | $162K |
| 74183 | <1% | 368 | $161K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,113 | $161K |
| 72100 | <1% | 1,743 | $156K | |
| 86901 | <1% | 8,635 | $150K | |
| 82247 | <1% | 45,279 | $146K | |
| 84075 | <1% | 42,076 | $142K | |
| 83970 | <1% | 3,042 | $141K | |
| 93971 | <1% | 319 | $135K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 508 | $134K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 11,187 | $131K |
| 84450 | <1% | 39,852 | $130K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,444 | $126K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,992 | $125K |
| 76642 | <1% | 1,573 | $122K | |
| 73130 | <1% | 2,141 | $117K | |
| 77066 | Tomosynthesis, mammo | <1% | 906 | $116K |
| 84520 | <1% | 63,665 | $115K | |
| 73110 | <1% | 2,052 | $115K | |
| 74018 | <1% | 1,977 | $111K | |
| 77080 | <1% | 660 | $103K | |
| 84702 | <1% | 10,866 | $100K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,059 | $94K |
| 85610 | <1% | 37,247 | $94K | |
| 82947 | <1% | 56,640 | $94K | |
| 86141 | <1% | 9,592 | $92K | |
| 73564 | <1% | 788 | $88K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 410 | $86K |
| 81003 | <1% | 55,555 | $85K | |
| 82728 | <1% | 6,740 | $85K | |
| 99199 | Unlisted special service, procedure or report | <1% | 1,772 | $79K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,842 | $78K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,051 | $77K |
| 83690 | <1% | 24,357 | $76K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,777 | $76K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 8,080 | $74K |
| 82310 | <1% | 19,683 | $71K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,845 | $71K |
| 73140 | <1% | 1,459 | $70K | |
| 72170 | <1% | 597 | $68K | |
| 73502 | <1% | 967 | $67K | |
| 82607 | <1% | 4,115 | $64K | |
| 76380 | <1% | 844 | $61K | |
| 87088 | <1% | 20,629 | $61K | |
| 84484 | <1% | 22,546 | $60K | |
| 83550 | <1% | 7,263 | $60K | |
| 83735 | <1% | 15,977 | $54K | |
| Z7502 | <1% | 1,695 | $54K | |
| 70496 | <1% | 234 | $53K | |
| 76870 | <1% | 634 | $53K | |
| 86780 | <1% | 4,842 | $53K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 445 | $52K |
| 86480 | <1% | 854 | $52K | |
| 0637 | <1% | 89,696 | $52K | |
| 82570 | <1% | 8,096 | $49K | |
| 73080 | <1% | 830 | $47K | |
| 82043 | <1% | 6,624 | $46K | |
| 88342 | <1% | 268 | $45K | |
| 83540 | <1% | 7,302 | $43K | |
| 70498 | <1% | 188 | $42K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,090 | $42K |
| 73221 | <1% | 169 | $42K | |
| 73560 | <1% | 570 | $42K | |
| 70544 | <1% | 203 | $41K | |
| 71101 | <1% | 364 | $41K | |
| 83520 | <1% | 2,174 | $40K | |
| 87040 | <1% | 14,626 | $40K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 404 | $39K |
| 93970 | <1% | 57 | $38K | |
| 86803 | <1% | 2,989 | $37K | |
| 70486 | <1% | 291 | $37K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,348 | $36K |
| 80076 | <1% | 4,669 | $36K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,429 | $36K |
| 73590 | <1% | 586 | $35K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 23,886 | $35K |
| 84156 | <1% | 7,976 | $34K | |
| 82040 | <1% | 7,792 | $34K | |
| 82746 | <1% | 2,147 | $32K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 153 | $31K |
| 87536 | <1% | 317 | $31K | |
| 0250 | <1% | 11,541 | $30K | |
| 87340 | <1% | 3,620 | $30K | |
| 87449 | <1% | 2,369 | $29K | |
| 83605 | <1% | 9,813 | $29K | |
| 83615 | <1% | 5,422 | $28K | |
| 82248 | <1% | 12,878 | $27K | |
| 86762 | <1% | 2,008 | $26K | |
| 83021 | <1% | 1,497 | $26K | |
| 76801 | <1% | 288 | $25K | |
| 72141 | <1% | 108 | $25K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 290 | $25K |
| 84153 | <1% | 1,269 | $25K | |
| 84439 | <1% | 3,334 | $25K | |
| 72197 | <1% | 55 | $24K | |
| 84100 | <1% | 7,181 | $24K | |
| 86787 | <1% | 2,051 | $23K | |
| 72040 | <1% | 349 | $23K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 415 | $22K |
| 84165 | <1% | 1,749 | $22K | |
| 82784 | <1% | 1,009 | $22K | |
| 93880 | <1% | 24 | $22K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 287 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,258 | $21K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 980 | $20K |
| 85652 | <1% | 9,635 | $20K | |
| 90674 | <1% | 1,263 | $18K | |
| 84403 | <1% | 679 | $18K | |
| 73100 | <1% | 248 | $17K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,914 | $17K |
| 87324 | <1% | 1,643 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 527 | $15K |
| 86923 | <1% | 139 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,754 | $14K |
| 72050 | <1% | 123 | $14K | |
| 70491 | <1% | 58 | $14K | |
| 86038 | <1% | 1,294 | $14K | |
| 83655 | <1% | 2,005 | $14K | |
| 73660 | <1% | 227 | $14K | |
| 85730 | <1% | 3,934 | $13K | |
| 86880 | <1% | 292 | $13K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,485 | $13K |
| 73090 | <1% | 237 | $12K | |
| 82950 | <1% | 2,996 | $12K | |
| 85379 | <1% | 3,317 | $12K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,937 | $12K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 856 | $12K |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 726 | $12K |
| 87210 | <1% | 3,423 | $12K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,552 | $11K |
| 76881 | <1% | 104 | $11K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 477 | $10K |
| 84550 | <1% | 2,712 | $10K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 2,065 | $10K |
| 86704 | <1% | 991 | $10K | |
| 86765 | <1% | 755 | $10K | |
| 82378 | <1% | 524 | $10K | |
| 80306 | <1% | 1,419 | $9K | |
| 82550 | <1% | 2,426 | $9K | |
| 83721 | <1% | 1,067 | $9K | |
| 90686 | <1% | 847 | $9K | |
| 73501 | <1% | 104 | $9K | |
| 96367 | <1% | 409 | $9K | |
| J3490 | Unclassified drugs | <1% | 5,596 | $8K |
| 74022 | <1% | 69 | $8K | |
| 82077 | <1% | 1,907 | $8K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 716 | $8K |
| 74181 | <1% | 12 | $8K | |
| 86317 | <1% | 703 | $8K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 52 | $8K |
| 81513 | <1% | 88 | $7K | |
| 86225 | <1% | 453 | $7K | |
| 84134 | <1% | 572 | $7K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 406 | $7K |
| 87205 | <1% | 2,565 | $7K | |
| 73552 | <1% | 86 | $7K | |
| 83718 | <1% | 1,017 | $7K | |
| 0258 | <1% | 2,955 | $6K | |
| 81015 | <1% | 1,753 | $6K | |
| 74019 | <1% | 47 | $6K | |
| 82105 | <1% | 334 | $6K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 153 | $6K |
| 87081 | <1% | 3,112 | $6K | |
| 87497 | <1% | 124 | $6K | |
| 97161 | <1% | 901 | $6K | |
| 86665 | <1% | 300 | $6K | |
| 82951 | <1% | 412 | $6K | |
| 84146 | <1% | 334 | $6K | |
| 84132 | <1% | 1,557 | $5K | |
| 74174 | <1% | 12 | $5K | |
| 78306 | <1% | 13 | $5K | |
| 80197 | <1% | 306 | $5K | |
| 73120 | <1% | 47 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,784 | $5K |
| 85046 | <1% | 900 | $5K | |
| J1815 | Injection, insulin, per 5 units | <1% | 3,860 | $5K |
| 85014 | <1% | 2,065 | $5K | |
| 86677 | <1% | 551 | $5K | |
| 87186 | <1% | 1,932 | $5K | |
| 73060 | <1% | 62 | $4K | |
| 80179 | <1% | 1,172 | $4K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,276 | $4K |
| 86160 | <1% | 164 | $4K | |
| 87481 | <1% | 125 | $4K | |
| 72070 | <1% | 42 | $4K | |
| 82465 | <1% | 1,121 | $4K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,312 | $4K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,702 | $4K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,368 | $4K |
| 83993 | <1% | 177 | $4K | |
| 86003 | <1% | 87 | $4K | |
| 74170 | <1% | 13 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 88 | $3K |
| 90656 | <1% | 445 | $3K | |
| 0710 | <1% | 928 | $3K | |
| P9021 | Red blood cells, each unit | <1% | 113 | $3K |
| 86364 | <1% | 245 | $3K | |
| 76706 | <1% | 25 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,995 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 110 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,992 | $3K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,145 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,348 | $2K |
| 84145 | <1% | 754 | $2K | |
| 70547 | <1% | 12 | $2K | |
| 86664 | <1% | 151 | $2K | |
| 90715 | <1% | 122 | $2K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 748 | $2K |
| 87070 | <1% | 559 | $2K | |
| 73070 | <1% | 30 | $2K | |
| 90662 | <1% | 323 | $2K | |
| 85018 | <1% | 680 | $2K | |
| 90688 | <1% | 136 | $2K | |
| 86635 | <1% | 206 | $2K | |
| 83935 | <1% | 320 | $2K | |
| 73000 | <1% | 31 | $2K | |
| 0370 | <1% | 1,009 | $2K | |
| 86360 | <1% | 166 | $2K | |
| 84295 | <1% | 484 | $2K | |
| 72081 | <1% | 30 | $2K | |
| 82962 | <1% | 1,993 | $2K | |
| 82952 | <1% | 387 | $2K | |
| 83001 | <1% | 130 | $2K | |
| 86769 | <1% | 80 | $2K | |
| 86431 | <1% | 319 | $1K | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,419 | $1K |
| 82670 | <1% | 49 | $1K | |
| 77061 | <1% | 17 | $1K | |
| 86359 | <1% | 166 | $1K | |
| 83930 | <1% | 277 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 183 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 579 | $1K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,310 | $1K |
| 84155 | <1% | 315 | $1K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 441 | $1K |
| 82140 | <1% | 146 | $1K | |
| 87631 | <1% | 25 | $1K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 744 | $1K |
| 73600 | <1% | 13 | $1K | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 185 | $1K |
| 80164 | <1% | 112 | $1K | |
| 86308 | <1% | 231 | $998.27 | |
| 88304 | <1% | 180 | $910.57 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 199 | $850.17 |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 14 | $842.83 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 76 | $826.26 |
| 86256 | <1% | 39 | $810.00 | |
| 73650 | <1% | 12 | $765.00 | |
| 80162 | <1% | 41 | $737.80 | |
| 82627 | <1% | 26 | $660.00 | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 17 | $640.40 |
| 82150 | <1% | 101 | $596.70 | |
| 82390 | <1% | 49 | $592.00 | |
| 85384 | <1% | 204 | $563.86 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 315 | $538.00 |
| 83010 | <1% | 38 | $485.33 | |
| 82103 | <1% | 26 | $469.00 | |
| 85045 | <1% | 146 | $465.01 | |
| 0255 | <1% | 124 | $456.18 | |
| 86140 | <1% | 1,510 | $455.24 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 15 | $434.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 181 | $404.22 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 161 | $389.22 |
| 82705 | <1% | 63 | $367.00 | |
| 82330 | <1% | 29 | $356.38 | |
| 86334 | <1% | 12 | $343.00 | |
| 86335 | <1% | 13 | $342.00 | |
| 0272 | <1% | 118 | $340.24 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 237 | $328.23 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 582 | $318.43 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 642 | $309.99 |
| 87807 | <1% | 89 | $280.99 | |
| 82977 | <1% | 30 | $279.00 | |
| 86255 | <1% | 13 | $278.00 | |
| 84270 | <1% | 12 | $276.00 | |
| 86301 | <1% | 13 | $265.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 276 | $230.93 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | <1% | 14 | $219.11 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 135 | $206.87 |
| 82274 | <1% | 40 | $206.00 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 263 | $195.71 |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 22 | $193.75 |
| 90756 | <1% | 30 | $192.96 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 107 | $185.48 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 140 | $175.09 |
| 89051 | <1% | 33 | $172.00 | |
| 82985 | <1% | 40 | $170.00 | |
| 86376 | <1% | 13 | $169.00 | |
| 80202 | <1% | 20 | $142.25 | |
| 83002 | <1% | 25 | $132.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 57 | $127.16 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 359 | $122.85 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 401 | $114.11 |
| 86735 | <1% | 12 | $102.00 | |
| 82805 | <1% | 14 | $92.30 | |
| 87102 | <1% | 13 | $90.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 58 | $60.56 |
| 87045 | <1% | 31 | $59.05 | |
| 82272 | <1% | 37 | $56.00 | |
| C1769 | Guide wire | <1% | 14 | $38.32 |
| 80320 | <1% | 213 | $37.20 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 123 | $35.24 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 15 | $27.65 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 595 | $27.52 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 82 | $26.74 |
| 90749 | <1% | 25 | $25.01 | |
| 84478 | <1% | 43 | $21.64 | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 30 | $17.47 |
| 87046 | <1% | 12 | $16.83 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 39 | $6.74 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13 | $5.73 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 132 | $5.41 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 84 | $2.81 |
| 3044F | <1% | 1,357 | $0.01 | |
| 47562 | 0% | 12 | $0.00 | |
| 3051F | 0% | 38 | $0.00 | |
| 87338 | 0% | 12 | $0.00 | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 0% | 25 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| 3046F | 0% | 12 | $0.00 | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 0% | 85 | $0.00 |
| 80324 | 0% | 14 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 15 | $0.00 |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 0% | 15 | $0.00 |
| 80359 | 0% | 14 | $0.00 | |
| 80329 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAPPLIN-JONES, CAMILLE (SENIOR VICE PRESIDENT/AREA MANAGER)